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Abstract
Vitamin A and its active metabolite retinoic acid are essential for embryonic development and 
adult homeostasis. Surprisingly, excess or deficiency of vitamin A and retinoic acid can cause 
similar developmental defects. Therefore, strict feedback and other mechanisms exist to regulate 
the levels of retinoic acid within a narrow physiological range. The oxidation of vitamin A to 
retinal has recently been established as a critical nodal point in the synthesis of retinoic acid, and 
over the past decade, RDH10 and DHRS3 have emerged as the predominant enzymes that regulate 
this reversible reaction. Together they form a codependent complex that facilitates negative 
feedback maintenance of retinoic acid levels and thus guard against the effects of dysregulated 
vitamin A metabolism and retinoic acid synthesis. This review focuses on advances in our 
understanding of the roles of Rdh10 and Dhrs3 and their impact on development and disease.
INTRODUCTION
Vitamin A (retinol) is an organic nutrient that is essential for human embryonic development 
and adult homeostasis. More specifically, during embryogenesis, sufficient levels of vitamin 
A are critical for brain, craniofacial, limb, and organ patterning and morphogenesis.1–3 
Later, in adulthood, vitamin A plays important roles in fertility, immune function, 
maintenance of vision, and skeletal homeostasis.4–6 Vitamin A is available to the human diet 
in two distinct forms: preformed vitamin A (retinol and its esterified form, retinyl ester) and 
provitamin A carotenoids. Provitamin A carotenoids serve as the principle source of vitamin 
A within the food chain and, include α-carotene, β-carotene, and β-cryptoxanthin which are 
derived from plants. Preformed vitamin A is typically found in foods of animal origin, 
including dairy products, fish, and meat (especially liver) and most of the body’s vitamin A 
is stored in the liver in the form of retinyl esters.
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Both provitamin A and preformed vitamin A are metabolized intracellularly via two 
sequential oxidation reactions to all-trans-retinoic acid (ATRA), the active form of vitamin 
A, which elicits essential biological functions. In the first reaction which is reversible, 
retinol is oxidized to form all-trans-retinal. In the second reaction, all-trans-retinal is 
irreversibly oxidized to ATRA. ATRA is a ligand for each of the three mammalian isotypes 
of the retinoic acid receptors (RARs), namely RARα, β, or γ,7–10 which form heterodimers 
with one of three different isotypes of the retinoid X receptor (RXR): RXRα, β, or γ.11 The 
RAR–RXR heterodimers associate with genomic elements consisting of direct repeats (DRs) 
termed retinoic acid response elements (RAREs) found in the promoter or vicinity of target 
genes (Figure 1).
In the classical model of retinoid signaling, RAR–RXR heterodimers associate with RAREs 
in the presence of corepressors, histone deacetylases, and methyltransferases, which 
maintain target genes in a transcriptionally silent state. Upon ATRA ligand binding, RAR–
RXRs dissociate from corepressors and recruit coactivators resulting in transcriptional 
activation.12 However, deviations from this classical model have been identified in which 
binding of ATRA to RAR–RXRs has been shown to recruit corepressors to silence gene 
activation. Repression of gene expression by retinoic acid was first identified in the 
restriction of the homeobox B1 (Hoxb1) gene.13 Other deviations to the classical model have 
been found as in the case of fibroblast growth factor 8 (Fgf8),14,15 as wells as, in the 
differential regulation of the paired homeobox proteins, by upregulation of PHOX2A and 
downregulation of PHOX2B.16 Many of the genes controlled by RAR–RXRs play 
significant roles in cellular differentiation and developmental programming; thus, gene 
regulation by RAR–RXRs play critical roles in developmental patterning, differentiation of 
tissues, and organogenesis during embryonic development.1,3,17,18 Furthermore, following 
birth, RAR–RXR-based signaling continues to play important roles in postnatal life in a 
wide array of processes such as the immune response, germ cell function, metabolic 
regulation, neuronal plasticity and tissue differentiation, regeneration, and repair.19–23
The mechanisms that regulate the formation of ATRA in embryos and the plethora of 
developmental processes in which ATRA plays a critical role have been the subject of 
several excellent and recent reviews.3,24–27 However, the long established dogma that (1) 
oxidation of all-trans-retinol to all-trans-retinal was carried out solely by medium-chain 
alcohol dehydrogenase (ADH) enzymes, and did not serve an important role in the 
regulation of ATRA synthesis; and (2) that primary control of ATRA synthesis occurred 
solely at the second oxidative step has been overturned.28–30 In the current review, we 
therefore first describe new developments and changing paradigms in our understanding of 
the feedback regulation of ATRA levels in embryonic tissues. Second, we focus on the new 
directions and ideas regarding the role of ATRA during developmental programming.
Morphogenesis and pattern formation during embryogenesis are driven by a multitude of 
signaling molecule gradients that orchestrate specific programs of gene expression and 
ultimately determine cell fate. ATRA signaling via RAR–RXR contributes to establishing 
cell fate by acting as a positional morphogen.31,32 Information derived by an ATRA-
responsive cell from the cellular levels of ATRA is integrated with positional and temporal 
Shannon et al. Page 2













information derived from other morphogen gradients allowing the cell to make complex fate 
decisions.33
The actions of ATRA come from its function as an autocoid, acting near its site of synthesis 
due to its short half-life and relatively lipophilic composition. In many developmental 
processes, ATRA acts in a noncell autonomous fashion whereby the developmental fate of 
an ATRA-responsive cell population, which cannot synthesize ATRA, is regulated by a 
neighboring ATRA-synthetic cell population. Noncell autonomous modes of signaling for 
ATRA have been proposed in the case of the developing kidney34 and brain vascular 
development.35 In other processes, however, ATRA also acts in a cell-autonomous, autocrine 
fashion, that is, by directing the expression of genes within the same cell that synthesizes 
ATRA from a retinaldehyde precursor. For example, such autocrine effects of ATRA have 
been proposed in Sertoli cells.36 This type of autocrine signaling by ATRA is particularly 
important in situations where ATRA regulates its own levels and metabolism within the 
ATRA-synthetic cell.
Regulating the levels of a diffusible molecule like ATRA requires the cooperation of binding 
proteins and transporters, and of synthesis and catabolism enzymes. The levels of ATRA 
within tissues need to be very tightly regulated to ensure proper signaling. The factors 
involved in ATRA metabolism and transport are modulated by both ATRA-dependent and by 
ATRA-independent pathways37 and are responsive to the dietary or maternal levels of 
retinoid precursors.
It is important to consider that in nonlaboratory settings, the levels and/or composition of 
ATRA precursors such as preformed vitamin A and provitamin A carotenoids, vary 
considerably in the diet of different populations and even among different individuals within 
the same population. For example, Western diets are more reliant on animal products, which 
provide more preformed vitamin A and less provitamin A carotenoids than the diets 
available to the rest of the world’s populations.38,39
Vitamin A deficiency can have serious deleterious effects ranging from loss of vision, to 
impaired growth and risk of infection.40 Thus optimal levels of ATRA need to be maintained 
despite large individual differences in the absorption and conversion of provitamin A 
carotenoids.41 Ensuring that embryonic tissues receive appropriate levels of ATRA at each 
particular stage and time of development depends on cooperation between both maternal and 
fetal retinoid metabolic pathways and their ability to adapt to the availability of vitamin A, 
as well as the need for ATRA.
TERATOGENICITY OF EXCESS OR DEFICIENCY OF ATRA
A sufficient intake of vitamin A is critical for normal embryonic development;42–45 
however, administration of excess vitamin A or ATRA during early pregnancy can lead to 
congenital malformations of the head, heart, and limbs.46–50 Hypervitaminosis A has also 
been associated with abnormal conditions in adults such as an increased risk of bone 
fractures in the elderly,51–53 and in addition to teratogenic effects, pharmacological doses of 
ATRA can also cause toxicity associated with symptoms of retinoic acid syndrome.54 
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Paradoxically, similar congenital malformations have been observed in mothers that have 
ingested excess amounts of vitamin A during pregnancy or patients exposed to drugs based 
on ATRA or RAR-agonists, as in vitamin A-deficient patients and animal models.55,56 The 
overlapping spectrum of congenital malformations and conditions irrespective of excess or 
deficiency in vitamin A or ATRA is due to the fact that changes in the levels of embryonic 
ATRA alters basic developmental and homeostasis pathways.57
The spatiotemporal levels of ATRA in an embryo following adult exposure to a 
pharmacological dose of ATRA, is subject to the time of exposure, the efficiency of transport 
of ATRA across the placenta, and the pharmacokinetics and distribution of ATRA in each 
tissue of the fetus. While in the past, exogenous ATRA administration to pregnant female 
mice was used to examine the effects of excess levels of embryonic ATRA, a recent study of 
the immediate and late effects of ATRA administration on mouse fetal development has 
painted a more complex picture. Even though a pharmacological dose of ATRA can initially 
result in an excess of ATRA in the embryo, this excess is followed by induction of ATRA-
deficiency in the recovery period.58 More specifically, within 6 h postexogenous 
administration of ATRA to the mother, the levels of ATRA in mouse embryos can be found 
in 1800-fold excess compared to untreated embryos. However, after an additional 6 h, the 
levels of embryonic ATRA diminish to the extent they become equal in treated versus 
untreated embryos. The embryonic levels of ATRA then continue to fall in treated embryos, 
such that by 24 h they are up to 33% lower than normally seen in untreated embryos.
The progression from short-term excess to long-term deficiency following administration of 
exogenous ATRA is most likely a result of the increased clearance of ATRA and 
compensatory enzymatic activities by maternal and embryonic tissues trying to cope with 
excess levels of ATRA. Similar, compensatory activity is also observed following genetic 
deletion of the different RARs which leads to the generation of teratogenic levels of ATRA.
59 Therefore, the pharmacokinetic profile of an acute dose of ATRA consists of a short 
period of ATRA excess in the embryo immediately after administration, followed by a long 
state of ATRA deficiency.
The surprising finding that many of the deleterious effects of exogenous ATRA 
administration could be corrected by a subsequent dose of ATRA58 led to the conclusion that 
prolonged ATRA deficiency which follows an acute excess of ATRA, is responsible, at least 
in part, for many of the deleterious effects caused by exposure to pharmacological doses of 
ATRA. In fact, it is evident that ATRA deficiency induced by ATRA administration is more 
prolonged and has more toxic effects, than an acute change in the hours immediately 
following administration. Even modest changes in the embryonic levels of ATRA can result 
in developmental defects if these perturbations persist for a sufficiently long period of time. 
For example an increase in the steady state level of ATRA of only 40% in early mouse 
embryos results in teratogenic effects through E14.5. Similarly, decreases in the steady state 
levels of endogenous ATRA of comparable magnitude also elicit developmental defects.
25,60,61
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MOLECULAR DETERMINANTS OF RETINOID METABOLISM IN EMBRYONIC 
TISSUES
Uptake and Transport of Retinoids and Carotenoids
Provitamin A carotenoids are a significant source of dietary vitamin A in humans.39 
Carotenoids are absorbed in the intestine and are transported in the circulation by association 
with lipoproteins, mostly chylomicrons.62,63 Carotenoids are taken up by several organs and 
tissues such as the liver, eye, ovaries, and fat. Although embryonic tissues primarily receive 
preformed vitamin A, there is evidence that provitamin A carotenoids can also be converted 
to ATRA within the fetus.60 Provitamin A carotenoids, which represent carotenoids with one 
unsubstituted β-ionone ring, are oxidatively cleaved to produce retinaldehyde by the enzyme 
β-carotene-15,15-dioxygenase 1 (BCDO1; Figure 1).64–66 BCDO1 is expressed at high 
levels in the enterocytes of the intestine and also in other tissues such as hepatic stellate and 
parenchymal cells in the liver, in mammary tissue, keratinocytes, and the kidney, as well as 
in embryonic tissues.67–69 The expression of BCDO1 is negatively regulated by the 
intestine-specific transcription factor ISX which itself is induced by ATRA via RAR.70–73
Preformed vitamin A (retinol and retinyl esters) is hydrolyzed in the intestinal lumen by 
several lipases with broad specificity and then is taken up by enterocytes through facilitated 
transport or passive diffusion (reviewed in Refs 74 and 75). Retinol is re-esterified within the 
enterocytes primarily through the actions of lecithin retinol acyltransferase (LRAT).76 
Within the enterocyte, esterification of retinol is also enhanced in the presence of cellular 
retinol-binding protein II (CRBPII), which binds retinol with high affinity at low nanomolar 
concentrations.76–79 Postprandial retinyl esters and carotenoids are secreted from the 
intestine as part of chylomicrons, the bulk of which are taken up by liver as chylomicron 
remnants. However, chylomicrons can also deliver retinoids to some target tissues including 
the embryo via the placenta.80–82 Circulating carotenoids and retinyl esters are also found 
associated with lipoproteins including very low density lipoproteins.83,84 Retinyl ester-
containing chylomicron remnants are endocytosed by hepatocytes and hydrolysed through 
the activity of several carboxylesterases and lipases.84,85 Other ester hydrolases found in 
target tissues, such as lipoprotein lipase, hydrolyze retinyl esters from chylomicrons and 
allow cells to take up the free retinol.82,86 It is important to note that a significant amount of 
unesterified retinol is secreted in the portal circulation independent of apolipoproteins and 
that this pathway may be important in certain pathological conditions.74
The main mode of transport for retinoids is via blood circulation and the most efficient 
delivery system for retinoids to embryonic tissues is in the form of retinol associated with 
serum retinol binding protein (RBP), or more specifically RBP4 (Figure 1). During postnatal 
life, RBP4 is secreted by hepatocytes which transport retinol to most target tissues including 
the placenta. Within the fetus, RBP4 is secreted by both fetal hepatocytes and the visceral 
yolk sac which facilitates the transport of retinol from the placenta to the embryonic sites of 
ATRA synthesis.87,88 The importance of RBP4 was demonstrated in adult mice carrying 
RBP4 null mutations as they displayed decreased fertility as well as severe structural 
changes to the retina with accompanying decreases in vision.89,90 The role of RBP4 in 
delivering retinol to the placenta and from the placenta to embryonic tissues is evident in the 
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developmental delay and abnormalities associated with impaired synthesis of either maternal 
and/or the fetal-derived RBP.81
RBP interacts with several surface receptors on target tissues. The best known RBP receptor 
is stimulated by retinoic acid 6 (STRA6) which is found in many organ–blood barriers, in 
the retinal pigment epithelium (RPE), choroid plexus, and Sertoli cells, as well as epidermal 
keratinocytes, dermal fibroblasts, and the placenta.91–94 STRA6 plays a critical role in 
allowing tissues such as the RPE and the choroid plexus to import retinol from the retinol–
RBP complex referred to as holo-RBP.93,95–97 Although it was previously suggested that 
STRA6 couples with CRBP1 to internalize retinol,98,99 a recently determined cryo-EM 
structure of STRA6 suggests that STRA6 mediates internalization of retinol by diffusion 
through the cellular membrane.100 In cases where there is an excess of serum RBP unbound 
to retinol, or apo-RBP, and unesterified retinol within the cytoplasm, STRA6 can mediate 
efflux of cellular retinol to apo-RBP (Figure 1).99,101,102 A second RBP4 receptor (RBPR2) 
is found in the small intestine and hepatocytes, and is thought to potentially play a role in the 
reverse transport of retinol to the liver.103
The exact mechanism for maternal-fetal transfer of retinol from holo-RBP4 across the 
placenta to the developing fetus remains to be determined. Importantly, however, it has been 
shown that neither maternal, nor fetal RBP4 can cross the placenta.104 There is clear 
evidence that the delivery of retinol via holo-RBP4 to the placenta is receptor-
mediated105– 107 and that STRA6 is one possible placental RBP receptor.108 But what 
mediates the transfer of retinol from the maternal placenta to the embryonic circulation is 
currently unknown. Similarly, it is also not known whether this transfer involves a 
transcellular or a paracellular pathway, or both.
Among the many issues and unanswered questions regarding the targeting and transport of 
RBP4 across the placenta, one of the most important is the relevance of extrapolating 
findings derived from mouse models to human biology. For example, there are important 
differences between rodents and humans in terms of placental development and even in 
terms of the role of the visceral yolk sac which functions throughout murine pregnancy but 
is mostly a vestigial structure in humans after the first trimester.109,110 There are also 
species-specific differences in the extent of retinoid delivery to the fetus mediated by 
lipoprotein-based transport of retinyl esters. Therefore beyond initial reports,111,112 there has 
been a paucity of studies investigating the mechanisms of retinol delivery across the human 
placenta.
What we do know is that LRAT is critically required for the uptake of retinol from plasma 
by target tissues such as RPE cells through binding to Stra6.113 LRAT also plays an 
important role in the formation of retinyl esters in quiescent hepatic stellate cells, the body’s 
principal vitamin A storage site under normal physiological conditions (Figure 1). Although 
stellate cells represent approximately 8% of the total cells in a healthy liver, they store 80–
90% of the liver’s retinoid content which is equivalent to 50–80% of the total retinoid stores 
of the body.114 As in the intestine, esterification of retinol in the liver and in the RPE is 
enhanced in the presence of cellular RBPs, in this case, CRBP1.115–117 Hydrolysis of retinyl 
esters stored in the liver or in target tissues can be carried out by several potential enzymes. 
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Of note, hormone-sensitive lipase and patatin-like phospholipase domain-containing 3 - 
(PNPLA3) have been implicated in the hydrolysis of retinyl esters in adipose tissue and 
hepatic stellate cells, respectively (Figure 1).118–120 However, it is likely that there are 
several other enzymes capable of such activity in adipose tissue, hepatic stellate cells, and 
RPE.
Regulation of Vitamin A Uptake, Transport, and Storage
In the case of circulating forms of retinoids, ATRA controls the expression levels of the 
receptors of serum RBP, namely, STRA6 and RBPR2. While the expression of STRA6 is 
induced by ATRA via RARγ,121–123 the expression of the liver RBP4 receptor, RBPR2, is 
repressed by ATRA and is negatively correlated with liver retinoid status.103 ATRA also 
controls the expression levels of CRBP1 and CRBP2 which play important roles in 
channeling ligands to and from cellular receptors and/or enzymes.124,125 In general, the 
expression of both CRBP1 and CRBP2 is increased in response to ATRA acting via 
RAR/RXR on several well-characterized RARE sequences found in their promoters. 
However, the levels of expression of CRBP2 in the small intestine are increased in the case 
of vitamin A deficiency, suggesting additional mechanisms may result in differential 
expression of these accessory proteins in specific tissues.126
Several mechanisms allow for cells to regulate the levels of retinyl esters to respond to 
vitamin A deficiency or to accommodate an intake of dietary vitamin A. Feedback 
regulation by ATRA signals vitamin A status and affects the uptake, delivery, and storage of 
retinol as retinyl esters.74 ATRA augments the formation of retinyl esters through 
upregulation of LRAT.127,128 These changes allow tissues to increase their storage of 
vitamin A in times of supply and also help tissues avoid forming excess ATRA from free 
retinol. The activity of BCDO1 also appears to regulate the activity and expression of LRAT 
and other acyltransferases and thereby influence the formation of retinyl esters in the fetus. 
Interestingly, the mechanism by which this occurs does not involve cleavage of its known 
substrate β-carotene.60,129 Our knowledge of the intracellular retinyl ester hydrolases 
operating within the liver, RPE, adipose tissue, and other tissues to store retinoids remains 
rudimentary. However, retinyl ester hydrolases play a critical role in the uptake of retinol 
from retinyl esters as well as in determining the availability of retinol for ATRA. Thus, this 
process is likely to be tightly regulated. In support of this idea, the expression of the retinyl 
ester hydrolase, PNPLA3 in hepatic stellate cells, is inversely correlated with unesterified 
retinol availability.120
Interconversion of Retinol and Retinaldehyde
The first step in the metabolism of vitamin A to ATRA is the oxidation of all-trans-retinol to 
all-trans-retinal (Figure 1). For many years, it was commonly thought that cytosolic ADHs 
were primarily responsible for this reaction during embryogenesis and that they carried out 
the reaction ubiquitously and redundantly. The primary reasons for this idea lay firstly in the 
observation that Adh7 was ubiquitously expressed during embryogenesis. Secondly, 
although Adh1 and Adh4 exhibit tissue specific domains of activity,130 Adh1−/−, Adh4−/−, 
and Adh7−/− loss-of-function mouse models survive into adulthood without evidence of 
developmental defects.131–133 The lack of a discernible developmental phenotype in Adh 
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loss-of-function models therefore led to the idea that primary control for the synthesis of 
ATRA occurred at the second step through retinaldehyde dehydrogenase (RALDH) 
oxidation of retinal to ATRA. In support of this idea, Raldh2 loss-of-function mouse mutants 
exhibited diminished ATRA synthesis in association with considerable developmental 
defects in heart, limb, and axial development.134
However, the long established dogma that (1) oxidation of all-trans-retinol to all-trans-retinal 
during embryogenesis was carried out solely by ADH enzymes and did not serve an 
important role in the regulation of ATRA synthesis; and (2) that primary control of ATRA 
synthesis occurred solely at the second oxidative step was overturned by the identification of 
the short-chain dehydrogenase, RDH10, and its role in the first oxidation step of vitamin A 
metabolism.28–30 The importance of RDH10 in embryonic development and ATRA 
synthesis and signaling was clearly revealed in hypomorphic Rdh10trex/trex and null 
Rdh10−/− mouse models which are embryonic lethal between E10.5 and E14.5 in association 
with insufficient ATRA production.28–30,129 Analysis of in vivo ATRA activity in null 
Rdh10−/− mutants carrying the RARE-lacZ transgene reporter, revealed a complete absence 
of RA production prior to E9.5.29 Similarly, In Rdh10trex/trex embryos, ATRA activity was 
completely absent in the craniofacial, trunk, and limb regions. Only a considerably 
diminished domain of activity remained within the neural tube (Figure 2).28,136,137 
Furthermore, in enzymatic assays, the Rdh10trex mutant allele was shown to be incapable of 
oxidizing vitamin A (retinol) to retinal.28 A further indication of RDH10’s critical role in 
this process is the substantial reduction of NAD-dependent retinol oxidase activity in Rdh10 
loss-of-function embryos.30 RDH10 is membrane bound in target cells and carries out the 
oxidation of all-trans-retinol within pools of the cellular membrane that are free of inhibitory 
RBP1.138
During embryogenesis, Rdh10 is dynamically expressed both temporally and spatially 
commencing around E8.0 within the prospective hindbrain and lateral mesoderm tissues.28 
Between E8.25 to E10.5, Rdh10 continues to be expressed in the lateral plate mesoderm, 
and dramatically expands to the somites, limb buds, head mesenchyme, primitive olfactory, 
optic, otic, lung, and foregut tissues.28 The spatiotemporal pattern of Rdh10 expression 
closely correlates with the spatiotemporal pattern of developmental defects observed in 
RDH10 loss-of-function mouse embryos. E9.5 Rdh10trex/trex mutants display duplicated or 
displaced otic vesicles and agenesis of the third to sixth caudal pharyngeal arches.28 By 
E10.5, Rdh10trex/trex mutant embryos exhibit truncated forelimbs28,29 with interdigital 
webbing that persists at E14.5136 (Table 1). Somitogenesis, or the process of forming 
somites, which are precursors of metameric vertebrae and muscle, is also perturbed in 
Rdh10trex/trex mutants.140 Furthermore, variable orofacial cleft phenotypes are evident in 
Rdh10trex/trex mutant embryos between E12.5 and E13.0 including a midline facial cleft of 
the frontonasal process in which the nasal septum and cavities fail to form.28 In addition, 
these mutants exhibit disruptions in organogenesis with defective development of the heart, 
lungs, liver, stomach, pancreas, and gastrointestinal tract (Table 1).28 Rdh10−/− null mutant 
embryos exhibit a more severe phenotype than Rdh10trex/trex embryos, which is consistent 
with a more complete loss of RA signaling.29 By E9.5, null Rdh10−/− mutants exhibit 
defective turning, axial elongation, and overall growth. Furthermore, the first pharyngeal 
arch is reduced in size and arches 2–6 fail to form. Rdh10−/− null mutants exhibit embryonic 
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lethality by E10.5, likely as a consequence of severe cardiac defects including failure to 
undergo looping and failure to form the proper heart chambers.29 Other more recently 
generated Rdh10 loss-of-function mouse models have revealed critical roles for Rdh10 and 
RA signaling in salivary gland development, brain vascular formation, juvenile 
spermatogenesis, and dark vision adaptation35,145–147 (Table 1).
Nonmammalian models have also contributed to our understanding of the role Rdh10 plays 
during embryogenesis and in the production and regulation of ATRA. The characterization 
of these models has helped to demonstrate the conserved role of RDH10 within several 
vertebrate species during embryogenesis. In zebrafish, rdh10a, is expressed in the paraxial 
mesoderm in early somite stage embryos148 and in the absence of rdh10a, zebrafish embryos 
exhibit a decrease in ATRA production and signaling. At 24 h postfertilization, this results in 
anteriorization of the nervous system, together with enlarged hearts and increased numbers 
of cardiomyocytes.144 The phenotype is considerably worsened when rdh10a is depleted in 
combination with aldh1a2 (raldh2), the primary enzyme responsible for the second oxidation 
step of vitamin A metabolism.144
Interestingly, depletion or inhibition of RA synthesis results in an increase in Rdh10 
expression.29,148,149 Conversely, exposure to exogenous RA has the opposite effect of 
decreasing Rdh10 expression. These findings are indicative of a negative feedback 
mechanism in which Rdh10 is inactivated when sufficient levels of ATRA have been 
produced. In further support of this idea, Rdh10 possesses a putative RARE in its 5′ 
upstream enhancer control region suggesting this feedback may be direct.29 Thus, loss-of-
function studies in animal models support a role for RDH10 as the predominant and earliest 
acting enzyme in the oxidation of retinol to retinal during embryonic development. The 
interconversion of all-trans-retinol to all-trans-retinal by RDH10 is therefore now recognized 
as an important spatiotemporal control or nodal point in the synthesis of ATRA, which 
assists in regulating the levels of ATRA during embryogenesis to help guard against vitamin 
A toxicity.
Although RDH10 is currently considered the most important retinol dehydrogenase present 
in the early embryo, there are other enzymatic activities that contribute to retinaldehyde 
formation and retinoid function later in life. For example, two additional retinol 
dehydrogenases, RDH1 and DHRS9, play important roles in postnatal retinoid metabolism 
in adipose tissue and astrocytes, respectively.150,151 Furthermore, several soluble enzymes 
belonging to classes I, III, and IV ADH enzymes have been shown to play a role in postnatal 
retinol metabolism by protecting against vitamin A toxicity.131,152–154
It is important to note that the oxidation of retinol to retinal is reversible and the reduction of 
all-trans-retinal to retinol is particularly important in the conversion of β-carotene to retinol 
for storage and transport to target tissues (Figure 1). Many retinaldehyde reductases have 
been identified in the eye (reviewed in Ref 155) and the reduction of all-trans-retinaldehyde 
is critical for vision.156 However, despite the well-recognized roles for retinaldehyde 
reductases, the identity of individual reductases with physiological relevance in tissues, 
besides the eye, remain to be determined.
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Recently, we and others described a role for the short-chain dehydrogenase/reductase (SDR) 
family, member 3 (DHRS3) in reducing retinaldehyde to retinol.135,139,141,157,158 Dhrs3 is 
expressed in a dynamic spatiotemporal pattern that overlaps with many tissues in which 
vitamin A metabolism and signaling are known to occur during mouse embryogenesis. The 
highest levels of DHRS3 protein in E14.5 embryos are observed in the liver, kidney, nasal 
epithelium, and interdigital zones of limbs (Figure 2). In the heart, high levels are found in 
the pericardial mesothelium, while in the neural tube, high levels of activity are found along 
the dorsal and ventral midline. In the brain, DHRS3 also localizes to the developing 
pituitary, cerebellum, and choroid plexus and has been observed in the retina, thyroid, lung, 
and intestine (Figure 2).135 In addition to mouse embryos, DHRS3 is known to be active in 
human testes, liver, and small intestine tissues.157
Loss-of-function studies in mice have demonstrated that Dhrs3−/− is critical for normal 
embryogenesis as mutant embryos dye during late gestation, around E17.5 to E18.5.135 
Similar to models of Rdh10 loss-of-function, Dhrs3−/− mutant embryos display perturbed 
craniofacial, heart, and axial development (Figure 2 and Table 1).135 In the head, the palatal 
shelves fail to elevate and then also fail to fuse, resulting in cleft palate. Cardiac anomalies 
present in the form of ventricular septal defects, atrial septal defects, and double-outlet right 
ventricle. In the axial skeleton, vertebral fusions, specifically at C1 and C2 occur, as wells as 
delayed ossification within the jaw, and skull.135 In Dhrs3−/− mice containing the RARE-
lacz transgenic reporter, ATRA activity was shown to be increased in the majority of tissues 
compared to wild-type littermates with expanded domains particularly in the frontonasal 
region and tail145,146 (Figure 2). Notably, the Dhrs3−/− mutants which displayed the largest 
increase in ATRA activity tended to exhibit the most severe developmental defects.
In addition to mice, other species-specific models have validated the role of DHRS3 in 
vitamin A metabolism and embryogenesis providing evidence for its conserved role between 
vertebrate species. For example, a reduction of dhrs3a in zebrafish leads to increased ATRA-
reporter activity and activation of ATRA-target genes.148 More specifically, the knockdown 
of dhrs3a results in an expanded domain of ATRA signaling which encompasses the anterior 
portion of the spinal cord and part of the hindbrain including rhombomeres 7/8. This impacts 
nervous system patterning and results in a reduced number of neurons known as T-
interneurons in the hindbrain.148 Similarly, morpholino knockdown of dhrs3 in Xenopus 
embryos also produced a phenotype characteristic of ATRA excess. Xenopus dhrs3 
morphants presented with smaller heads that were reduced in diameter. In addition, the 
mutants also exhibit altered neuroectoderm patterning as well as defects in somitogenesis, 
including diminished gene expression and perturbed segmentation.141
Although DHRS3 is the primary retinaldehyde reductase known to be present in embryonic 
tissues, it may not be the only retinaldehyde reductase to play a role in embryogenesis. 
Interestingly, residual retinaldehyde reductase activity can be detected in microsomes and 
mouse embryonic fibroblasts (MEF) derived from Dhrs3−/− mice.139 Consistent with this 
observation, it is known that retinaldehyde reduction can also be carried out in vitro by 
several members of the aldo-keto-reductase (AKR) family. However, it remains to be 
determined whether AKR enzymes play such an in vivo role during embryogenesis.
24,159–162 Despite this uncertainty, it is clear DHRS3 has well-defined physiological 
Shannon et al. Page 10













relevance based on the alterations in systemic ATRA metabolism, RAR-signaling, and 
developmental defects observed in Dhrs3 mutant fish, amphibian, and mouse embryos.
135,139,141,148
Although members of three distinct enzyme families have been implicated in the 
interconversion of retinol and retinaldehyde based on enzymatic activities demonstrated in 
vitro, only in limited instances has a definitive in vivo role in ATRA metabolism been 
corroborated by loss-of-function approaches. To date, RDH10 and DHRS3 are the only 
retinol/retinaldehyde oxidoreductases whose ablation has been shown to result in 
developmental defects. The lack of an apparent developmental phenotype (except in the eye) 
in animals deficient in other retinoid-specific SDR, ADH, or AKR enzymes does not rule 
out the possibility that additional enzymes play a role in retinol/retinaldehyde 
interconversion. Rather the indispensable role of RDH10 and DHRS3 during embryonic 
development could reflect the fact that they are expressed earlier than other potential retinol/
retinaldehyde oxidoreductases, or that they are expressed in a tissue or tissues where no 
compensatory activities exist.
Formation and Breakdown of ATRA
The second step in the metabolism of vitamin A to ATRA is the oxidation of retinal to 
ATRA. The conversion of retinaldehyde to ATRA is an irreversible reaction catalyzed by 
several retinaldehyde dehydrogenases ALDH1A1, ALDH1A2, and ALDH1A3 (formerly 
RALDH1, RALDH2, and RALDH3) which belong to the aldehyde dehydrogenase family.
163–166 Of these, ALDH1A2 appears to be the most broadly active during early 
embryogenesis.164,167 ALDH1A2 plays a critical role in the conversion of retinaldehyde into 
ATRA in the spinal cord, developing heart, retina, lung, and inner ear olfactory epithelium.
134,168–171 Aldh1a3 is expressed in sensory neuroepithelia and plays an important role in 
ATRA formation in the developing nasal structures and eye.172–175 Aldh1a1 is expressed in 
the developing neural retina, and many tissues after birth, however, a deficiency of Aldh1a1 
does not result in apparent developmental defects. Rather, Aldh1a1 loss-of-function 
influences lipid metabolism in postnatal life in response to increased levels of retinaldehyde.
167,176–181 In addition to ALDH1A1–3, several cytochrome P450 enzymes, can oxidize 
retinaldehyde to ATRA, and CYP1B1 in particular has been shown to contribute to the 
formation of ATRA in vivo.182,183
Regulation of ATRA Formation and Breakdown
The physiological levels of ATRA are tightly regulated to guard against the effects of either 
ATRA deficiency or excess. ATRA levels are modulated through a negative feedback 
mechanism, which serves to regulate ATRA-synthetic enzymes in the presence of elevated 
ATRA levels. Consistent with this mechanism Aldh1a1, Aldh1a2, and Aldh1a3184–186 are 
downregulated in response to increasing concentrations of ATRA. Furthermore, RDH10, the 
principal enzyme responsible for oxidation of retinol to retinal during embryogenesis was 
also shown to be downregulated in response to exogenous ATRA or elevated endogenous 
levels of ATRA as seen in Dhrs3−/− mice.29,135,148,149
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A critical regulatory control point in the metabolism of vitamin A and synthesis of ATRA 
occurs at the first step in the reversible interconversion of retinol and all-trans-retinal. The 
function of the oxido-reductase enzymes, RDH10 and DHRS3, is to help alleviate excess as 
well as deficient levels of ATRA. DHRS3, by reducing retinaldehyde, leads to a decrease in 
the ATRA precursor and, therefore, protects tissues from the formation of excess ATRA. The 
expression of DHRS3 is responsive to ATRA levels and creates a negative feedback loop to 
further restrict the formation of ATRA.141,148,187,188 The oxidation of retinol to all-trans-
retinal by RDH10 serves the reverse function of DHRS3 by protecting against a retinoid 
deficiency. This oxidative step can be modulated in the presence of excessive levels of 
ATRA by downregulating expression of RDH10,135 which acts as part of the negative 
feedback mechanism to prevent further synthesis of ATRA. Conversely, in response to a 
deficiency in ATRA such as in the case of Raldh2 loss-of-function, the activity of RDH10 
can increase in an attempt to compensate.29
Another level of regulation in the interconversion of retinol to all-trans-retinal occurs 
through an interplay between RDH10 and DHRS3 which form a complex. RDH10 and 
DHRS3 are codependent as DHRS3 relies on RDH10 to maintain its full catalytic activity. 
Similarly, RDH10 requires interaction with DHRS3 for complete activation.139 This 
interaction has been corroborated in cell culture studies by demonstrating colocalization of 
the two proteins. Additionally, Rdh10 and Dhrs3 exhibit overlapping regions of activity.
28,135 For example, Rdh10 and Dhrs3 have been shown to be expressed in the interdigital 
regions of the hindlimbs of E12.5–14.5 mouse embryos which supports the potential for 
their direct physical interaction.139 However, future studies aimed at thoroughly 
characterizing the coexpression of theses enzymes in tissues throughout embryogenesis are 
still critically needed.
The interaction and subsequent activation of DHRS3 by RDH10 acts to reduce the levels of 
excess ATRA. In MEF derived from Dhrs3−/− mutant embryos, the production of retinol 
from retinaldehyde is diminished, and furthermore, cells coexpressing both Rdh10 and 
Dhrs3 produce less retinaldehyde and ATRA.139 Therefore, in the instance of excess ATRA, 
DHRS3, which is upregulated by ATRA, interacts with RDH10 enabling it to begin 
converting retinaldehyde back to retinol, thereby preventing its conversion by ALDH 
enzymes to ATRA. In the presence of RDH10, retinol may be converted back to 
retinaldehyde; however, the overall production of ATRA from retinaldehyde is greatly 
reduced in the presence of DHRS3, thereby protecting against ATRA excess. It is through 
this interplay between RDH10 and DHRS3, and the interconversion of retinol and 
retinaldehyde, that ATRA can be reduced in times of excess without stopping its production 
completely. This allows for the precise regulation of ATRA production, which helps guard 
against harmful teratogenic effects to the developing embryo.139
CONCLUSIONS
Vitamin A (retinol) and its active metabolite ATRA are essential for normal embryonic 
development and adult homeostasis as defects can arise in these processes in association 
with either retinoid excess or deficiency. Therefore, in periods of both vitamin A and ATRA 
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excess or deficiency, compensatory mechanisms that regulate uptake, delivery and storage of 
retinol exist to maintain ATRA levels within a tight physiological range.
The oxidation of retinol to retinal and its reversible interconversion, which are mediated 
predominantly by RDH10 and DHRS3 respectively, have now been firmly established as 
critical control or nodal points in vitamin A metabolism and the synthesis of ATRA (Figure 
1). Both RDH10 and DHRS3 are essential for embryonic development (Table 1) and 
together these enzymes form a codependent complex that helps to maintain appropriate 
levels of ATRA. It is through complex mechanisms including the precise regulation provided 
by RDH10 and DHRS3, that embryos and adults are protected against the potentially 
harmful effects of dysregulated levels of vitamin A and ATRA.
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Preformed vitamin A is taken up from the intestinal lumen by enterocytes and transported 
via the blood supply as all-trans-retinol to its various target tissues. Large stores of vitamin 
A are kept in hepatic stellate cells of the liver by esterification of all-trans-retinol to retinyl 
esters. Mobilization of these stores is carried out by hydrolysis of retinyl esters back to all-
trans-retinol where it is then transported by the blood supply through binding to RBP4. At 
target tissues, the RBP receptor, STRA6, allows for the import of retinol associated with 
RBP4. Once inside the cell, retinol associates with the RDH10/DHRS3 complex in the first 
reversible step of vitamin A metabolism to be oxidized to all-trans-retinaldehyde by RDH10. 
All-trans-retinaldehyde can then be reduced back to all-trans-retinol by DHRS3, or it may be 
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further oxidized by the ALDH genes (ALDH1A1–ALDH1A3) to form ATRA. ATRA then 
serves as a ligand for one of three isotypes of the RARs which form a heterodimer with 
RXR. The RAR–RXRs associate with retinoic acid response elements (RARE) within the 
promoters of target genes and can induce both transcriptional activation and silencing.
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(a–p) Lateral and dorsal views of E9.5, E10.5, E12.5, and E14.5 control RARE-LacZ, 
Rdh10trex/trex; RARE-LacZ, and Dhrs3−/−;RARE-LacZ embryos illustrating diminished 
retinoic acid signaling in the craniofacial and trunk regions of Rdh10trex/trex embryos and 
expanded regions of signaling in the frontonasal region and tail of Dhrs3−/− embryos. (q) 
Lateral view of LacZ expression in a bisected E14.5 Rdh10bgeo/+ embryo revealing RDH10 
activity in the upper and lower lip, nasal epithelium, neural tube, heart, gut, and interdigital 
zone of the limbs. (r) Lateral view of an E14.5 embryo section immunostained with anti-
DHRS3 (red) and DAPI (blue) illustrating DHRS3 activity in the neural tube, heart, liver, 
kidney, and nasal epithelium; g, gut; h, heart; id, interdigital zone of the limbs; ki, kidney; li, 
liver; ul, upper lip; ll, lower lip; nt, neural tube; ne, nasal epithelium. Panels (g)–(i) were 
adapted from Ref 135.
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TABLE 1
Recorded Developmental Defects for Animal Models of Rdh10 and Dhrs3 loss-of-function
Phenotype Rdh10 Dhrs3
Lethality Rdh10trex/trex E10.5 to E14.528 Dhrs3−/− E17.5135
Rdh10−/− E10.528
Craniofacial Clefting Palatogenesis
Rdh10m366Asp E10.5 midline facial cleft61 Dhrs3−/−:
Rdh10trex/trex: E14.5 palatal shelves fail to elevate135
E12.5–E13.0 frontonasal process displays variable clefting28 E18.5 clefting of the secondary palate139
E12.5–E13.0 defective formation of the nasal septum and 
chambers28
Somites Somitogenesis Somitogenesis
Rdh10trex/trex 8–15 somite stage consistently smaller somites 1–6; 
somite size normalizes from somite 7 onward140
Xenopus defective somitogenesis141
Skeletal Rdh10trex/trex E14.5 lack atlas and axis vertebrae140 Axial skeleton
Dhrs3−/− E14.5/E17.5 abnormal axial skeleton 
development; vertebral fusions and delayed 
ossification135
Limb development Forelimb growth No recorded developmental defects
Rdh10trex/trex and Rdh10−/− E10.5–E13.0 stunted forelimb growth, 
however, normal hindlimb morphology3,28,29,61,142
Interdigital webbing
E14.5 fail to lose interdigital mesenchyme61,136
Brain Hindbrain patterning Rdh10−/− E7.75 defective hindbrain 
patterning142,143
No recorded developmental defects
Brain Vasculature
Rdh10 ENU induced mutant E14.5 long, thin neocortex with 
reduced numbers of blood vessels. Large diameter blood vessels in 
PNVP vasculature35
Organogenesis Heart Heart
Rdh10trex/trex E9.5 heart edema and looping effects28 Dhsr3−/− defective cardiac outflow tract formation; 
defects in atrial and ventricular separation135
Rdh10−/− fail to undergo looping and chamber formation29
Xenopus enlarged heart with increased cardiomyocyte number144
Eyes
RPE-specific Rdh10 knockout at 6wks impairments in 11-cis-




E10.5 lung bud agenesis28
E12.5 to E13.0 hypoplasia28,142
Liver
Rdh10trex/trex E12.5 to E13.0 hypoplastic with fewer lobes28,142
Pancreas
Rdh10trex/trex E12.5 to E13.0 structures not found28,142
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Phenotype Rdh10 Dhrs3
Salivary gland
Rdh10trex/trex E14.5 size reduction in submandibular salivary 
glands; normal morphology146
Stomach/Midgut
Rdh10trex/trex E12.5 to E13.0 hypoplastic28
Testes
Rdh10fl/fl,Amh-Cre+ juvenile male mice at 2–3 weeks defective 
sertoli cell differentiation of spermatogonial cells147
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